Education
About Us
Working with TipRanks
Follow Us
Kodiak Sciences Inc (KOD)
NASDAQ:KOD
KOD Stock Chart & Stats
$17.63
-$0.42(-4.39%)
At close: 4:00 PM EST
$17.63
-$0.42(-4.39%)
Day’s Range― - ―
52-Week Range$1.92 - $21.17
Previous CloseN/A
Volume87.32K
Average Volume (3M)905.21K
Market Cap
$931.25M
Enterprise Value$257.91M
Total Cash (Recent Filing)$104.17M
Total Debt (Recent Filing)$65.21M
Price to Earnings (P/E)―
Beta2.88
Next Earnings
Nov 12, 2025EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding52,821,690
10 Day Avg. Volume742,993
30 Day Avg. Volume905,208
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.48
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue9.68
Enterprise Value/Gross Profit-2.63K
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$20.33Price Target Upside15.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessKodiak’s bispecific anti-IL6/VEGF, KSI-101, shows greater reductions in central subfield thickness and better drying of intraretinal fluid compared to Roche’s monospecific anti-IL6, vamikibart.
Market PotentialKSI-101 has the potential to achieve best-in-class efficacy, with pivotal data from PEAK and PINNACLE studies expected in the future.
Safety And EfficacyThe follow-up data from Kodiak Sciences’ Phase 1b APEX study shows consistent maintenance of strong OCT reductions and slight improvements in visual acuity gains, with no additional treatment-related adverse events.
Bears Say
Financial ConcernsKodiak Sciences has a short interest of 12.9% and a limited cash runway with only 0.5 years of cash left.
Market Opportunity LimitationsKOD's tarcocimab is in GLOW2 ph.III for DR with data expected, but there is an expectation of limited market opportunity due to low VEGF use in NPDR patients without DME.
Unproven PlatformDe-risking of Kodiak’s enhanced formulation design remains critical due to former Phase 3 trial failures and unexpected adverse events over time for tarcocimab.
Kodiak Sciences News
KOD FAQ
What was Kodiak Sciences Inc’s price range in the past 12 months?
Kodiak Sciences Inc lowest stock price was $1.92 and its highest was $21.17 in the past 12 months.
What is Kodiak Sciences Inc’s market cap?
Kodiak Sciences Inc’s market cap is $931.25M.
When is Kodiak Sciences Inc’s upcoming earnings report date?
Kodiak Sciences Inc’s upcoming earnings report date is Nov 12, 2025 which is in 3 days.
How were Kodiak Sciences Inc’s earnings last quarter?
Kodiak Sciences Inc released its earnings results on Aug 13, 2025. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.068 by $0.038.
Is Kodiak Sciences Inc overvalued?
According to Wall Street analysts Kodiak Sciences Inc’s price is currently Undervalued.
Does Kodiak Sciences Inc pay dividends?
Kodiak Sciences Inc does not currently pay dividends.
What is Kodiak Sciences Inc’s EPS estimate?
Kodiak Sciences Inc’s EPS estimate is -1.04.
How many shares outstanding does Kodiak Sciences Inc have?
Kodiak Sciences Inc has 52,821,690 shares outstanding.
What happened to Kodiak Sciences Inc’s price movement after its last earnings report?
Kodiak Sciences Inc reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.068. Following the earnings report the stock price went up 16.473%.
Which hedge fund is a major shareholder of Kodiak Sciences Inc?
Currently, no hedge funds are holding shares in KOD
Kodiak Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.33 (15.31% Upside)
$20.33 (15.31% Upside)
Blogger Sentiment
Neutral
KOD Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 249.0 Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
266.52%
12-Months-Change
Fundamentals
Return on Equity
-140.33%
Trailing 12-Months
Asset Growth
-36.07%
Trailing 12-Months
Company Description
Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
KOD Stock 12 Month Forecast
Average Price Target
$20.33
▲(15.31% Upside)
Technical Analysis
Urogen Pharma
―
Nurix Therapeutics
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
34.72% Insiders
8.07% Mutual Funds
49.60% Other Institutional Investors
0.09% Public Companies and
Individual Investors